Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
featured
Published in Oncology

Expert Opinion / Conference Coverage · June 12, 2017

Ten Practice Changes I Will Make After Attending ASCO 2017

Written by
Jeffrey J. Kirshner MD, FACP, FASCO

 

 Save  Recommend
 Share

Additional Info

  1. Shi Q, Sobrero AF, Shields AF, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract LBA1.
  2. Fizazi K, Tran N, Fein LE, et al. LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract LBA3.
  3. Adams S, Schmid P, Rugo HS, et al. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 1008.
  4. Adams S, Loi S, Toppmeyer D, et al. MPhase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 1088.
  5. Von Minckwitz G, Procter MJ, De Azambuja E, et al. APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract LBA500.
  6. Fuchs CS, Doi T, Jang RW-J, et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 4003.
  7. Janjigian YY, Ott PA, Calvo E, et al. Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 4014.
  8. Thomas RJ, Williams MMA, Mutilib M, et al. A double blind, randomised placebo controlled trial evaluating the effect of a pholyphenolic rich plant based nail bed balm on the severity of chemotherapy-induced onycholysis. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 10103.
  9. Kim J-Y, Ok O-N, Seo JJ, et al. A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 10108.
  10. Tawbi HA-H, Forsyth PAJ, Patrick A, et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 9507.
  11. Long GV, Atkinson V, Menzies AM, et al. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 9508.
  12. Hoskin P, Misra V, Hopkins K, et al. SCORAD III: Randomized noninferiority phase III trial of single-dose radiotherapy (RT) compared to multifraction RT in patients (pts) with metastatic spinal canal compression (SCC). Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract LBA10004.
  13. Raut CP, Espat NJ, Maki RG, et al. Extended treatment with adjuvant imatinib (IM) for patients (pts) with high-risk primary gastrointestinal stromal tumor (GIST): The PERSIST-5 study. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 11009.
  14. D'Angelo SP, Mahoney MR, Van Tine BA, et al. A multi-center phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401). Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 11007.
  15. Burgess MA, Bolejack V, Van Tine BA, et al. Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 11008.
  16. Hyman DM, Laetsch TW, Kummar S, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract LBA2501.

Disclosure statements are available on the authors' profiles:

Jeffrey Kirshner MD, FACP, FASCO

Further Reading

Most Read This Week

Recently Updated